Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
about
A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine CandidatesVaccinations for Neuroinfectious Disease: A Global Health PriorityProspects for dengue vaccines for travelersDengue Fever: Causes, Complications, and Vaccine StrategiesA Tetravalent Sub-unit Dengue Vaccine Formulated with Ionizable Cationic Lipid Nanoparticle induces Significant Immune Responses in Rodents and Non-Human PrimatesHuman CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificityHistorical Perspectives on Flavivirus ResearchSuppressive effect of dengue virus envelope protein domain III on megakaryopoiesis.Mapping the dengue scientific landscape worldwide: a bibliometric and network analysisComplexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Development of Peptide Vaccines in Dengue.Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine.Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys.Antibodies against nonstructural protein 1 protect mice from dengue virus-induced mast cell activation.Advancing dengue vaccine development.Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone.Polyvalent vaccines: High-maintenance heroes.Recent Developments in Recombinant Protein-Based Dengue Vaccines
P2860
Q24282617-ACD35BB4-E2A3-41FF-B799-795182F89038Q26252588-41E086A0-E559-4113-85F1-EA59094306F2Q26314423-629997A3-D318-40A4-BC3D-3F90039D068AQ26700082-BFFA49E5-E194-49EB-88C3-3CA74F0DC030Q27116692-9E2E98F1-8315-4CD5-9607-00A6440BE49AQ28733418-DF4F7071-FB61-42E3-B2FC-B2064F3A8292Q29994534-045B8489-ECE1-453D-9503-E5AFDFF2AD65Q33442742-139080FD-764F-440E-A1E1-67BE9B3E50EAQ33583390-99AC9C51-079D-47B0-95E4-36FC9873D2DBQ39535403-105CBE79-D8B3-4AF3-A116-7C28D290139FQ40038715-17B12F3A-6D32-4EDD-B8D5-FE482B995E69Q40040450-C47DB5E9-0397-403A-8523-8374B8C2A1EEQ40053434-D0EDD59A-B702-4F6B-B06D-D5C19C4744DAQ40067512-C8BC7AC1-8BD3-4AFB-84EE-BD49CFA3E7BAQ49952058-611AB671-84DD-4F5C-AB84-2AC3B117C368Q50223468-2ED947C7-C547-4DE8-8EBC-F2DCC4E8BA8DQ55091602-CEDA7D24-B2EF-49FC-9173-5C0EF2B3FFFCQ56960671-45BB7E51-C875-487E-B425-01FEBB84B941
P2860
Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Development of TV003/TV005, a ...... e Sanofi-Pasteur CYD™ vaccine?
@en
Development of TV003/TV005, a ...... e Sanofi-Pasteur CYD™ vaccine?
@nl
type
label
Development of TV003/TV005, a ...... e Sanofi-Pasteur CYD™ vaccine?
@en
Development of TV003/TV005, a ...... e Sanofi-Pasteur CYD™ vaccine?
@nl
prefLabel
Development of TV003/TV005, a ...... e Sanofi-Pasteur CYD™ vaccine?
@en
Development of TV003/TV005, a ...... e Sanofi-Pasteur CYD™ vaccine?
@nl
P2860
P1476
Development of TV003/TV005, a ...... e Sanofi-Pasteur CYD™ vaccine?
@en
P2860
P304
P356
10.1586/14760584.2016.1115727
P577
2015-11-11T00:00:00Z